Metacognitive therapy for obsessive-compulsive disorder
The Efficacy of Metacognitive Therapy for Obsessive-compulsive Disorder
This study is testing if metacognitive therapy can help reduce obsessive-compulsive symptoms in people from China compared to a treatment that doesn't include therapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 12 Years to 60 Years |
| Sex | All |
| Sponsor | Northeast Normal University Academic / other |
| Locations | 1 site (Changchun, Jilin) |
| Trial ID | NCT06466057 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of metacognitive therapy in reducing obsessive-compulsive symptoms among a Chinese population. Participants will be randomly assigned to either receive metacognitive therapy or a control treatment without psychotherapy for a duration of 8 to 15 weeks. The study will assess changes in obsessive-compulsive symptoms and metacognitive beliefs using standardized measures before, after, and 12 weeks post-intervention. The goal is to determine if metacognitive therapy can significantly improve outcomes for individuals with obsessive-compulsive disorder.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with obsessive-compulsive disorder who have a junior high school education or higher and are willing to participate voluntarily.
Not a fit: Patients with severe psychotic symptoms, significant depression, or a history of substance abuse may not benefit from this therapy.
Why it matters
Potential benefit: If successful, this therapy could provide a new effective treatment option for patients suffering from obsessive-compulsive disorder.
How similar studies have performed: While metacognitive therapy is a relatively novel approach for OCD, similar studies have shown promising results in other populations, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * two psychiatrists with the title of Deputy Chief Physician or above jointly determine that the above diagnostic criteria were met * education level of junior high school or above, without mental retardation or audio-visual disorders * participation in the study is voluntary, and the informed consent is signed by the patient or his/her guardian Exclusion Criteria: * loss of or insufficient self-awareness, the presence of hallucinations, delusions, and other psychotic symptoms * the presence of severe depression, or self-inflicted suicidal attempts and behaviors * the presence of a history of alcohol or drug abuse * refusal of psychotherapy, or the ineffectiveness of those who had been involved in a full course of psychotherapy.
Where this trial is running
Changchun, Jilin
- Northeast Normal University — Changchun, Jilin, China (Recruiting)
Study contacts
- Study coordinator: Fan Jiang, Ph.D
- Email: Jiangf581@nenu.edu.cn
- Phone: 13943004788
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.